Bone Marrow Transplant Patients May Benefit From New Immune Research

"Our results suggest that targeting of interleukin 23, (IL-23), an immune substance secreted by donor marrow cells, may be a viable way to limit graft-versus-host-disease without limiting graft-versus-leukemia activity," says lead researcher Rupali Das, Ph.D.

The study was presented at the national BMT Tandem Meetings in Tampa, Fla., Feb. 11, 2009. Dr. Das is a postdoctoral fellow in pediatric hematology/oncology at the Medical College in the laboratory of William R. Drobyski, M.D., professor of medicine in neoplastic diseases, and principal investigator of this study. Dr. Drobyski practices at Froedtert Hospital.

In a recent study, the researchers found that donor mice with marrow cells incapable of producing IL-23, provided protection from graft-versus-host damage to the recipient's colon, but not to other organs.

They then conducted studies in which mice with leukemia received T cells from the marrow and spleen of IL-23-deficient donor mice. The recipient mice not only had longer survival times than those receiving T-cells from IL-23-producing mice, but also showed no evidence of leukemia. Mice transplanted with T cells capable of producing IL-23 all died of graft versus host disease.

The study was funded by the Midwest Athletes Against Childhood Cancer (MACC) Fund, a major donor that has been supporting cancer research at the Medical College since 1976, and the National Institutes of Health's National Heart, Blood and Lung Institute.